Trending event

Nutter and Halloran co-hosted the Executive Breakfast Series program “Roadmap to an IND: Managing the Iron Triangle of Investor Expectations, Product Development and FDA Clearance” on March 31. The breakfast program, the first in a series, provided insight into how to quickly and safely progress through the necessary milestones to help the next generation of high value therapeutics reach the clinic.

Panelists discussed a range of challenges faced by a modern biotechnology company such as balancing the pressures to compress timelines, generating viable data, building a strong IP portfolio, and obtaining a high value early exit, all while using limited resources.

Key discussion leaders included: 

• Greg Dombal, COO, Halloran Consulting Group 
• Phil Haydon, President & Co-Founder, GliaCure 
• Timothy Cooke, Ph.D., CEO, NovaDigm Therapeutics, Inc.